According to a recent Future Market Insights study, the global Andersen Tawil syndrome treatment market is expected to surpass an impressive valuation of US$ 1.9 Billion in 2023 and reach US$ 4.2 Billion by 2033, with an 8.26% CAGR. Rising government assistance, incentives for pharmaceutical companies, increased awareness among people and social groups, physician-to-physician communication to find effective treatment methods for rare diseases, an increase in patient facilities, and an increase in research incentives due to the prevalence of non-profit organisations that promote health to treat rare diseases will all contribute to the market’s expansion.

Request Sample Copy of Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16357

In recent years, easy international access to data on the Andersen-Tawil syndrome has aided associated research efforts, which aids in market expansion. Furthermore, increasing government investments and incentives for rare disease research are assisting in the creation of drug demand for Andersen Tawil syndrome. Furthermore, the increasing involvement of private and public organisations supporting treatment and raising awareness will have a positive impact on future developments. However, the low prevalence of the Andersen-Tawil syndrome and a lack of awareness continue to be a major issue for market participants. Misdiagnosis and undiagnosed cases continue to be major issues impeding industry growth. Furthermore, the high costs associated with rare disease research will stifle innovation and growth prospects, stifling growth.

There are few other factors that hold back growth of the global market, such as the challenges in the research and development, delay in diagnosis thereby delaying the treatment, limitations with respect to expertise, characteristic dearth of attractiveness from an economic standpoint, which eventually has resulted in the lack of commercial interest for private investors, lack of regulatory framework in developing economies coupled with lack of skilled healthcare personnel.

Key Takeaways

  • Increasing focus of the government to prioritize drugs for the treatment of rare diseases are expected to propel growth
  • Increasing participation of organizations to support the treatment and to create awareness is also anticipated to drive growth of the market.
  • Growth in R&D investments by the key players in the Andersen-Tawil Syndrome Market is also expected to aid in market expansion.
  • North America is expected to dominate the market of Andersen Tawil syndrome.
  • South Asia is projected to witness fastest growth during the forecast period.
  • Type 1 Andersen Tawil Syndrome is projected to dominate the market with 59% market share by 2033.

Increased government funding efforts aimed towards improving diagnostic procedures is anticipated to generate lucrative prospects for the participants in the Andersen-Tawil syndrome market. Non-profit organizations are playing key roles in raising awareness positively influencing market developments”, comments an FMI analyst.

Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-16357

Competitive Landscape

Key players in the Andersen Tawil Syndrome Market are: Teva Pharmaceuticals Ltd, Zydus Pharmaceuticals, Inc., Sun Pharmaceuticals Industries Ltd., Advanz Pharmaceuticals, Novartis AG, Mylan N.V, Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Viatris Inc., and Pfizer Inc.

Some recent developments in this market are:

  • In April 2021, Teva Pharmaceuticals was acquired by Karo Pharma Aktiebolag with the aim of gaining the European OTC brand portfolios and drug research including rare disease solutions. Also, Sun Pharmaceutical Industries Ltd. announced the acquisition of 66% ownership interest in Trikaal Mediinfotech, and AWACS, through its subsidiary ABCD Technologies LLP.
  • In December 2016, Strongbridge Biopharma plc has acquired U.S. commercialization rights for Keveyis from Taro Pharmaceutical Industries Ltd (a subsidiary of Sun Pharmaceutical Industries Ltd) for the treatment of periodic paralysis. Under the terms of agreement, Taro Pharmaceutical Industries Ltd to receive an upfront payment of USD 8.50 mm and is also eligible to receive additional future payments upon the achievement of certain sales unit milestones. The acquisition of U.S. rights expands company’s rare disease portfolio to include neuromuscular diseases.

Key Segments Profiled in the Andersen Tawil Syndrome Treatment Market Industry survey

Disease Type:

  • Type 1
  • Type 2

Drug Class:

  • Carbonic Anhydrate Inhibitors
  • Acetazolamide
  • Dichloropenamide
  • Antiarrhythmic Drugs
  • Amiodarone
  • Flecainide
  • Beta-Blockers
  • Atenolol

Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Buy Now@ https://www.futuremarketinsights.com/checkout/16357

More Valuable Insights 

Future Market Insights, in its new offering, presents an unbiased analysis of the Bullous Keratopathy market, presenting historical analysis from 2017 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of Disease type (Type 1, Type 2) By Drug class (Carbonic Anhydrate Inhibitors, Acetazolamide, Dichlorpenamide, Antiarrhythmic Drugs, Amiodarone, Flecainide, Beta-Blockers, Atenolol) By Distribution channel (Hospital Pharmacies, Retail pharmacies, Online Pharmacies) and by region (North America, Latin America, Europe, South Asia, East Asia, Oceania MEA)

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedInTwitterBlogs

Leave a comment

Your email address will not be published. Required fields are marked *